The Application axis of the Canine Cancer Screening market is divided into three principal segments: Early Detection, Treatment Monitoring, and Prognostic Assessment. Early Detection, accounting for roughly 55% of revenue, captures screenings performed on asymptomatic dogs to identify malignancies before clinical signs emerge, driving the largest share of test kits, laboratory services, and veterinary consultations. Treatment Monitoring, representing about 30% of the market, includes serial screenings that track tumor response to chemotherapy, radiotherapy, or surgical interventions, thereby sustaining recurring revenue streams through repeat testing. Prognostic Assessment, with an estimated 15% contribution, focuses on evaluating disease aggressiveness and likely outcomes, informing therapeutic choices and end‑of‑life planning. Together, these application categories shape the overall market size by aligning product development, pricing strategies, and reimbursement models with distinct clinical decision points, underscoring the importance of nuanced Canine Cancer Screening segmentation for stakeholders.